Headquartered in Rockville, MD Fiscal year ends December NASDAQ: MXCT maxcyte.com
MaxCyte, Inc. is a cell-engineering company. Its Flow Electroporation platform and SeQure gene-editing risk assessment services support the discovery, development and commercialization of next-generation cell therapies.
The company earns revenue from several sources:
- Instrument sales.
- Single-use processing assemblies (PAs) and consumables.
- Annual instrument licenses.
- Assay services.
- Strategic Platform License (SPL) agreements, which pay clinical milestones and commercial royalties as partners' therapies advance.
MaxCyte describes this as a razor/razor-blade model. As of September 30, 2026, it had 28 SPL agreements covering 13 clinical programs and one commercial program. In July 2026 it signed a multi-platform technology license with Genentech.
The company has agreed to acquire Akron BioProducts (Akron Bio), a supplier of GMP-grade cytokines, growth factors, human plasma-derived products, media and cryopreservation reagents. The deal is expected to close by year-end 2026 and to extend MaxCyte into viral ex-vivo cell therapy manufacturing workflows, with recurring consumables revenue. Updated
A $134 million company just agreed to buy Akron BioProducts for $151.8 million, a deal management says nearly doubles its revenue base. Revenue beat expectations the same morning, and standalone 2026 guidance moved up to at least $34.5 million. The acquisition is expected to close before year-end.
MaxCyte, Inc. is a cell-engineering company. Its Flow Electroporation platform and SeQure gene-editing risk assessment services support the discovery, development and commercialization of next-generation cell therapies.
The Wall Street consensus 12-month price target for MXCT is $4.11.